Christina Terragni, an accomplished inventor based in Wilmington, MA, has made significant strides in the field of biomedical research. With a total of three patents to her name, she has focused her efforts on developing innovative therapeutic solutions aimed at enhancing patient care and treatment outcomes.

Latest Patents

One of her most recent patents is titled "Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereof." This invention presents novel antigen binding peptides, which include antibodies or antibody fragments that selectively bind to factor XIa inhibitors and dual inhibitors of FXIa and plasma kallikrein. This groundbreaking work also outlines methods for mitigating the antithrombotic effects of FXIa inhibitors through the administration of these peptides. Additionally, it provides detection reagents and methods for determining the level of FXIa inhibitors in biological samples.

Another notable patent is focused on "Glypican-3-binding fibronectin based scaffold molecules." This invention offers polypeptides that comprise tenth fibronectin type III domains (Fn3), which possess binding capabilities to glypican-3. Moreover, it includes fusion molecules and drug conjugates designed for diagnostic and therapeutic applications related to glypican-3, showcasing the potential for advancements in targeted therapies.

Career Highlights

Christina Terragni currently works with Bristol-Myers Squibb Company, where her research contributes to the advancement of biopharmaceuticals. Her innovative approaches in drug development highlight her commitment to enhancing therapeutic strategies.

Collaborations

Throughout her career, Christina has collaborated with esteemed colleagues such as Ginger Chao Rakestraw and Stanley Richard Krystek, Jr. These professional partnerships have proven essential in driving forward the research initiatives within her field.

Conclusion

Christina Terragni's contributions to the biomedical field through her patents and collaborations reflect her innovative spirit and dedication to improving healthcare outcomes. As she continues to work at Bristol-Myers Squibb, her ongoing research holds the promise of making significant impacts on medical treatments and patient care.

Profile summary based on public USPTO records.